Core Viewpoint - The company, Stone Pharmaceutical Group, has received FDA approval for its self-developed siRNA drug SYH2061 injection, allowing clinical trials in the U.S. This drug is also approved for clinical trials in China starting October 2025 [1] Group 1: Product Details - SYH2061 is a first-in-class siRNA drug that targets complement protein C5 through GalNAc conjugation for liver-targeted delivery [1] - The drug is administered subcutaneously and is designed to effectively lower C5 levels, making it suitable for treating IgA nephropathy and other complement-mediated diseases [1] Group 2: Clinical Development - This product is the first domestically developed siRNA drug to enter clinical trials in China with a long-lasting effect on reducing C5 levels [1] - Preclinical studies indicate that SYH2061 outperforms similar siRNA products in terms of drug activity and duration of effect, showcasing its potential clinical development value [1]
石药集团(01093.HK)双链小干扰RNA药物“SYH2061注射液”在美国获临床试验批准